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Abstract: Small nucleolar RNAs (snoRNAs) are non-coding RNAs involved in RNA modification 
and processing. Approximately half of the so far identified snoRNA genes map within the intronic 
regions of host genes, and their expression, as well as the expression of their host genes, is 
dependent on transcript splicing and maturation. Growing evidence indicates that mutations and/or 
deregulations that affect snoRNAs, as well as host genes, play a significant role in oncogenesis. 
Among the possible factors underlying snoRNA/host gene expression deregulation is copy number 
alteration (CNA). We analyzed the data available in The Cancer Genome Atlas database, relative to 
CNA and expression of 295 snoRNA/host gene couples in 10 cancer types, to understand whether 
the genetic or expression alteration of snoRNAs and their matched host genes would have 
overlapping trends. Our results show that, counterintuitively, copy number and expression 
alterations of snoRNAs and matched host genes are not necessarily coupled. In addition, some 
snoRNA/host genes are mutated and overexpressed recurrently in multiple cancer types. Our 
findings suggest that the differential contribution to cancer development of both snoRNAs and host 
genes should always be considered, and that snoRNAs and their host genes may contribute to 
cancer development in conjunction or independently. 
Keywords: Cancer; intronic snoRNA; H/ACA box; C/D box; CNA; copy number alteration; 
amplification; deletion; host gene; expression alteration 
 
1. Introduction 
Small nucleolar RNAs (snoRNAs) are non-coding RNAs of 60-300 nucleotides in length which 
are involved in fundamental molecular processes, such as RNA modification and processing. Even 
though some snoRNAs have been known for decades, hundreds have only recently been identified, 
and to date their number is over 700. Approximately half of the so-far identified snoRNA genes map 
within the intronic regions of both protein-coding genes or long-noncoding sequences whose 
function is, in some cases, poorly understood. Most snoRNA host genes belong to the 5′-terminal 
oligopyrimidine (5′-TOP) family, whose transcripts start with an oligopyrimidine tract [1,2], allowing 
for a specific expression regulation during cellular growth and proliferation [3]. Many of the protein-
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coding genes encode for ribosomal proteins, translation factors, or other proteins involved in 
ribosome biogenesis, suggesting the need for a balanced synthesis of these proteins and their 
corresponding snoRNAs. Intronic snoRNAs are transcribed by RNA polymerase II (Pol II) and are 
released from their transcripts (mRNAs or long noncoding RNAs (lncRNAs) precursors depending 
on the type of the host gene) through a process involving splicing and trimming [4,5]. 
The remaining half of snoRNA genes map within DNA intergenic regions, are endowed with 
independent promoters and are transcribed by Pol II or Pol III either as independent units, or as 
polycistronic structures [5]. 
The vast majority of snoRNAs can be divided into two main structural classes: H/ACA box 
snoRNAs, characterized by a double hairpin, separated by a hinge region containing the H box, and 
an ACA box close to the 3′ terminus; and C/D box snoRNAs, containing the C box close to the 5′ 
terminus, and the D box near to the 3′ end (reviewed in [6]). snoRNAs bind to specific proteins to 
form small nucleolar ribonucleoproteins (snoRNPs), complexes designated for RNA modification. 
H/ACA snoRNAs bind to NOP10, GAR1, NHP2, and dyskerin (DKC1), and guide the 
pseudouridylase activity to modify specific uridines (reviewed in [7]). Similarly, C/D box snoRNAs 
bind to NOP56, NOP58, 15.5 kDa, and Fibrillarin (FBL), and guide the 2′-O-Methylation of specific 
rRNA sugar residues [8]. In both cases, the target of the modification is determined by sequence 
complementarity between the guide and the target RNA, allowing Watson–Crick base pairing. 
However, a subgroup of snoRNAs, called “orphan” snoRNAs, do not match any RNA sequences, 
and their targets cannot be predicted [9]. Most of the known snoRNA targets are ribosomal RNAs 
(rRNAs), but recently other target types, such as messenger RNAs (mRNAs), have been 
identified[10]. In rRNA, 200 residues are modified by pseudouridylation or 2′-O-methylation, and 
these modifications are regarded to as fundamental steps in rRNA maturation and ribosome 
assembly, and for ribosomal function (reviewed in [6]).  
In addition, snoRNAs can be processed further to generate snoRNA-derived RNAs (sdRNAs), 
with features and functions similar to microRNAs (miRNAs) [11]. It is plausible that this processing 
is preferentially reserved to orphan snoRNAs, but it cannot be excluded a priori for other snoRNAs. 
Genetic instability is a common feature in many cancer types; genetic alterations involving 
protein-coding genes (among which are snoRNA host genes) are, in most cases, very well 
characterized. Conversely, the contribution to cancer onset of alterations occurring in non-coding 
DNA regions, is now becoming more and more clear after many years of neglect. Growing evidence 
indicates that mutations and/or deregulation affecting snoRNAs may play a significant role in 
oncogenesis, even though the mechanism by which snoRNA deregulation ultimately contributes to 
cancer onset remains, in most cases, unknown [12]. Deregulation of specific snoRNAs has been 
proposed to help in generating a cancer-prone setting by affecting different cancer-related cellular 
processes, like those controlling cellular growth, death, invasion and angiogenesis [13–15]. 
In this sense, many of the studies conducted on this topic have focused on the evaluation of the 
expression of snoRNAs and their matched host genes [16–19], while others were limited to the study 
of the mutations of a single snoRNA in a specific cancer setting [16,20–22]. In addition, co-occurrence 
of genetic alterations in snoRNAs and matched host genes should be taken under consideration, 
particularly for host genes for which a pro-oncogenic or tumor suppressive function has been 
ascribed. Here, we analyzed the copy number alterations (CNAs, i.e., amplifications and deep 
deletions) of 295 matched snoRNA-host gene couplets in more than 5 thousand cancer specimens 
from 10 different cancer types. Our results show that, in many cases, snoRNA and host gene-genetic 
alterations are coupled, but exceptions exist and should be considered when analyzing this kind of 
data. 
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2. Materials and Methods 
2.1. TCGA Data 
The data analyzed in this study were a TCGA (The Cancer Genome Atlas) project dataset of 5359 
patient-derived tumors representing 10 distinct human cancers (Table 1). For all of our TCGA study 
cases we analyzed the copy number counts and mRNA expression data, obtained from the cBioportal 
for Cancer Genomics (http://www.cbioportal.org/) [23,24]. The cBioPortal provides multidimensional 
cancer genomics data. The 10 cancer cohorts were chosen based on sample size and the availability 
of data regarding each pair of host-gene and snoRNA. In Table 1, the TCGA abbreviations for each 
tumor type with total sample number per tumor type are reported. 
Table 1. Summary of the tumor types, with acronyms and numerosity. 
 
Tumor 
Acronym 
Tumor  
Type 
Sample 
Number 
TCGA-HNSC Head and Neck squamous cell carcinoma 496 
 
TCGA-KIRC Kidney renal clear cell carcinoma 354 
 
TCGA-BRCA Breast invasive carcinoma 1070 
 
TCGA-COAD Colorectal adenocarcinoma 592 
 
TCGA-LUSC Lung squamous cell carcinoma 487 
 
TCGA-SKCM Skin Cutaneous Melanoma 367 
 
TCGA-LUAD Lung adenocarcinoma 511 
 
TCGA-UCEC Uterine Corpus Endometrial Carcinoma 509 
 
TCGA-OV Ovarian serous cystadenocarcinoma 398 
 
TCGA-GBM Glioblastoma multiforme 575 
The copy number alteration (CNA) dataset, downloaded from cBioPortal, was preprocessed 
using GISTIC2.0 [25]. The GISTIC pipeline allows to identify sections of the genome that are 
significantly amplified or deleted across a set of samples. The expression levels were quantified by 
RSEM (RNA-Seq by Expectation Maximization) [26], an accurate tool for quantifying transcript 
abundances from RNA-seq data; also these data were obtained from cBioPortal. 
We calculated the overall percentage of samples with copy number alterations co-occurring in 
host genes and snoRNA that belonged to 295 pairs extracted from the snoDB database 
(http://scottgroup.med.usherbrooke.ca/snoDB/) [27]. This provided us with alteration frequencies for 
each pair of host gene and snoRNA in ten human cancer types (Supplementary Table S1). 
2.2. Copy Number Alterations and Gene Expression Data  
The copy number status by sample was reported as −2 (Deep Deletion), −1 (Shallow Deletion), 0 
(Diploid status), 1 (Gain), 2 (Amplification) levels. Deep deletions refer to the homozygous deletions; 
Shallow deletion indicates a shallow loss e.g., heterozygous deletion; Diploid is the normal status; 
Gains refers to a low-level copy gain of gene; Amplifications indicate a high-level gene amplification. 
Gene expression levels were quantified by RSEM from RNA-Seq data and mRNA Z scores were 
computed using the tumors samples that were diploid for the corresponding gene. For each gene, Z 
score is equal to the difference between the specific expression of this gene in a specific sample and 
the average expression, over the standard deviation of this gene across samples, respectively. We 
classified as upregulated those genes with Z scores greater than 2 and downregulated those genes, 
with Z scores less than −2 (Supplementary Table S2). 
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2.3. Statistical Analyses 
Statistical analysis was performed using R (version 3.6.1) including R packages of data.table for 
data cleaning and management, tidyr for data clean-up, and ggplot2 for data visualization. Fisher’s 
exact test was used to assess associations between categorical variables (significant with p  <  0.05). 
3. Results 
3.1. snoRNAs and snoRNA Host Genes Alterations Vary Significantly in Different Cancer Types 
We first compiled a sno-RNA/host gene shortlist starting from the snoDB public database 
(http://scottgroup.med.usherbrooke.ca/snoDB/) [27]. A total of 295 snoRNA-host gene couples were 
chosen on the basis of the following criteria: 1. The snoRNA was included in the intronic region of 
either a protein-coding or a long non-coding mRNA gene; 2. the ensemble ID was available for the 
host gene and for the snoRNA. For the genes present in the shortlist, we analyzed the mutational data 
available from The Cancer Genome Atlas (TCGA) data portal relative to ten different cancer types:
 breast invasive carcinoma (BRCA), colorectal adenocarcinoma (COAD), glioblastoma 
multiforme (GBM), head and neck squamous cell carcinoma (HNSC), lung adenocarcinoma (LUAD), 
lung squamous cell carcinoma (LUSC), ovarian serous cystadenocarcinoma (OV), uterine corpus 
endometrial carcinoma (UCEC), skin cutaneous melanoma (SKCM), and kidney renal clear cell 
carcinoma (KIRC) (Table 1). These cancer types were specifically as they were found to contain higher 
mutation rates for the targets of interest.  
We analyzed the cumulative copy number alteration (CNA) frequency for each snoRNA/host 
gene couple, for the different tumor types, in terms of high-level amplifications or homozygous deep 
deletions. For 39% of the couples no CNA was detected in any of the tumor types queried (Table S1), 
suggesting that CNAs in each of these genes might confer a disadvantage in cell growth; for 10% of 
the couples CNA was detected to some extent throughout all of the different tumor types, while for 
the remaining 51% CNA was found in some tumors and not in others (Figure 1a).  
The tumor types with the higher snoRNA/host gene CNA frequencies turned out to be those of 
the OV group, followed by LUSC, BRCA, HNSC, and LUAD. The tumor types with the lowest 
cumulative CNA frequency were KIRC and GBM (Figure 1b). 
 
Figure 1. Occurrence of snoRNA/host gene alterations in the ten groups of cancers. (a) Percentage of 
copy number alterations (CNA) in snoRNA/host gene couples, across ten different tumor types 
(breast invasive carcinoma (BRCA), colorectal adenocarcinoma (COAD), glioblastoma multiforme 
(GBM), head and neck squamous cell carcinoma (HNSC), lung adenocarcinoma (LUAD), lung 
squamous cell carcinoma (LUSC), ovarian serous cystadenocarcinoma (OV), uterine corpus 
endometrial carcinoma (UCEC), skin cutaneous melanoma (SKCM), and kidney renal clear cell 
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carcinoma (KIRC)) divided between couples never undergoing CNA (red), undergoing CNA in all 
tumors (blue), and undergoing CNA only in some tumor types (green). (b) Cumulative CNA 
frequency in the ten tumor types, calculated in each series as total number of CNA events divided for 
the total number of possible alterations (i.e., the number of snoRNA/host gene couples (295) times the 
number of patients in the series). 
3.2. Copy Number Alterations of snoRNAs and Matched Host Genes are Not Always Coupled 
As the snoRNAs considered herein map within introns of other genes, it would be reasonable to 
postulate a concordance in their copy number alterations. However, the data we analyzed show that, 
in many cases, these assumptions are not correct. Indeed, when analyzing the CNA data for the 
snoRNA/host gene couples separately for each tumor type, it is clear that a co-occurrence of an 
amplification or deletion is not always the most frequent event. Indeed, there are cases where an 
amplification or deletion of the snoRNA does not co-occur with the same event in the host gene, and 
vice-versa (Figure 2a). Co-occurrence of CNA happened for about half of the mutant couples in the 
majority of the tumors, with striking exceptions for KIRCs (where co-occurrence happens 3 times 
more frequently) and BRCAs (where in more than half of the couples, alterations are not co-
occurring).  
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Figure 2. Co-occurrence of CNA in snoRNAs and host genes across different cancer types. (a) 
Percentage of co-occurrence of CNA in snoRNAs and host genes. Orange bars represent co-occurring 
mutations; brown bars represent mutations that do not co-occur, and purple bars represent absence 
of mutations. (b) Number of CNA events, normalized per sample, and represented with different 
colors in case of co-occurrence (orange), alteration in snoRNA but not in the host gene (light blue) or 
alteration in the host gene but not in the snoRNA (green). (c) Number of mutational events, split into 
amplification (red) and deletion (blue), and further into CNAs only involving snoRNAs (textured 
bars) and CNAs involving both snoRNA and host gene (filled bars). 
In addition, we wondered whether, when taking into consideration those alterations that fail to 
co-occur, these would be more frequently related to the snoRNA or to the host gene. To answer this 
question, we analyzed the average number of alterations per tumor sample. Strikingly, this analysis 
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revealed that the average number of alterations per sample varied greatly among different tumor 
types, with the lowest number in KIRCs, and the highest in OVs (Figure 2b). Secondly, CNAs in 
snoRNA not occurring in host genes were more frequent in BRCAs, OVs, LUADs, COADs, and 
SKCM, whereas CNAs in host genes not co-occurring in snoRNAs were more frequent in GBMs, 
UCECs, and LUSCs. In KIRCs and HNSCs the two events were found to be equally frequent (Figure 
2b). 
We next characterized the CNA events by identifying them as either amplifications or deletions. 
Within each tumor type, the number of amplifications or deletions in the snoRNA only group, and 
in the co-occurrence group was summed. Figure 2c represents the total number of each type of 
alteration, and is, by definition, influenced by the multiplicity of the series for each tumor type.  
3.3. Frequently Altered snoRNA-Host Gene Couples Recur in Different Cancer Types 
Apart from these general considerations, it is of particular interest to identify those snoRNA/host 
gene couples which vary more frequently across different tumor types. Indeed, among these there 
may be interesting targets with diagnostic or prognostic potential or useful for risk stratification of 
patients.  
For each tumor type, we selected a shortlist of the 10 snoRNA/host gene couples which undergo 
CNA most frequently in patients. As shown in Figure 3, some snoRNA/host gene couples recur in 
the top ten of more frequently altered couples, albeit with different frequencies, in different cancer 
types. The most prominent examples are those of SNORA63/EIF4A2, SNORA63E/LINC00888, 
SNORD66/EIF4G1. These couples undergo CNA in a significant portion of patients in HNSC, KIRC, 
SKCM, OV, and GBM; in all these tumor types, these 3 couples are altered in similar percentages of 
patients, ranging from 7%–8% in OV cancer, to over 40% in SKCM. Other couples recurring in 
multiple cancer types are SNORA15/CCT6A, altered in 5%–12% of cases of HNSC, KIRC, SKCM, and 
UCEC; SNORA14B/TOMM20, altered in close to 20% of COADs and, to a lower extent, in OV, UCEC, 
and GMB; SNORD72/RPL37, altered in over 10% of SKCM and, to a lower extent (4–8%) in HNSC, 
KIRC, and UCEC; SNORA56 and SNORA36A/DKC1, mutated in 0.5%–5% of HNSC, KIRC, BRCA, 
and UCEC patients; and SNORA70G/RAP1B, altered in 4%–5% of patients in HNSC, KIRC, and 
UCEC. 
Another aspect worthy of consideration is the very high overlap of genes mutated in the two 
lung cancer types assayed, adenocarcinoma and squamous cells carcinoma. In the top 10 altered 
couples for these tumor types, 9 are identical: SNORA13/EBP41L4A-AS1, SNORA27/RPL21, 
SNORA31/TPT1, SNORA71E/SNHG11, SNORA72/RPL30, SNORD102/RPL21, SNORD12/ZFAS1, 
SNORD12B/ZFAS1, and SNORD12C/ZFAS1. Strikingly, alteration frequencies of the 9 overlapping 
couples in the two tumor types are extremely similar, and range between 2.5% and 10% of patients.  
It is also interesting to note that BRCA, which is in the group of those with a higher recurrence 
of CNA per patient (Figure 2b), does not have any snoRNA/host gene couple recurring in more than 
2.5% of the patients (Figure 3). This may indicate that, in this specific pathology, alterations in 
snoRNAs and host genes may be related to a generalized genomic instability, and may therefore play 
a role as passenger mutations.  
Other snoRNA/host gene couples identified in the ten shortlists of frequently altered targets are 
shown in Figure 3 and are not detailed in the text. 
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Figure 3. Top snoRNA/host gene couples undergoing CNA in the ten different tumor types. For ease 
of interpretation, couples recurring in different tumor types have been assigned the same bar colors. 
3.4. Differential ExpressionAalterations of snoRNAs and Host Genes in Multiple Cancer Types 
We reasoned that copy number alterations likely impacts upon the differential expression of 
snoRNAs and host genes. Therefore, we extracted expression data for the targets of our interest from 
TCGA datasets. Data were analyzed in order to discriminate between over- or under-expression of 
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snoRNAs and host genes; over- or under-expression was determined by comparing the expression 
levels of each gene in the cancer population to those of the same gene in the reference population 
(constituted by all tumor samples profiled for that specific gene in TCGA). Figure 4a shows the 
average number per sample of over- or under-expression events, those events involving the host gene 
or the snoRNA being considered separately. As is clear from the image, over-expression events are 
much more frequent when compared to under-expression, and in general host-gene over-expression 
is detected 4-6 times more than snoRNA over-expression (with the exception of OV cancers, where 
the frequency for host gene over-expression is 20 times higher). In addition, it is striking that 
snoRNA-down regulation is never detected.  
We next looked at the cumulative frequency of expression alterations for the snoRNA/host gene 
couples. Since transcriptional down-regulation turned out to be a relatively infrequent event for our 
targets (Figure 4a), we decided to further analyze only the up-regulated snoRNA/host gene couples. 
Figure 4b shows, for each cancer type, the 10 couples with higher expression alteration frequencies. 
The first, remarkable observation is that alteration frequencies are fairly constant across different 
tumor types (and range around 5% for most targets), with the exceptions of GBM, where alteration 
frequencies are extremely low (below 0.1%), and LUSC and COAD, where, conversely, alteration 
frequencies are generally higher, arriving to 18%–25% for selected targets.  
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Figure 4. Alterations in gene expression for snoRNAs and host genes. (a) Number of expression 
alteration events, normalized per sample, and represented with different colors in case of higher 
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expression (red), lower expression (blue), and further split into expression alterations only involving 
snoRNAs (filled bars) or involving host genes (textured bars). (b) Top snoRNA/host gene couples 
undergoing expression alterations in the ten different tumor types. For easier interpretation, couples 
recurring in different tumor types have been assigned the same bar colors, and colors are matched to 
those assigned in Figure 3. 
Secondly, as observed for CNAs, some of the targets in the short-lists are common to different 
tumor types. For instance, SNORA71E/SNHG11 is in the top 10 of over-expressed targets in all tumor 
types, SNORA72/RPL30 is in the top 10 for all tumor types but KIRCs and OVs, and 
SNORA5C/TBRG4 is only missing in UCECs, OVs, and GBMs shortlists.  
Furthermore, it is worthwhile to note that less than half of the over-expressed targets are present 
in the shortlist of the couples undergoing CNA, suggesting that, in many cases, large amplifications 
and deletions of snoRNAs and of their host genes do not directly impact upon their expression.  
4. Discussion 
Somatic DNA copy number alterations (CNA) are nearly ubiquitous in cancer [28,29] and alter 
a greater portion of the cancer genome than any other type of somatic genetic alteration, playing 
important roles in oncogenesis and cancer therapy [29,30]. CNA can influence cancer gene expression 
regulation in several ways. There is indeed evidence that increased copy number can positively or 
negatively impact upon transcription, by altering dosage or by disrupting proximal or distant 
regulatory regions [31,32]. 
A growing number of reports in the literature have recognized a close connection between 
snoRNA alterations and cancer; however, many snoRNA genes map to intronic regions of other 
genes, and in most (but not all) cases, alterations occurring in snoRNAs are closely related to 
alterations in their host genes. Therefore, we believe that an analysis of the effects of snoRNAs 
alterations should always take into account the possible, co-occurring alteration of the matched host 
gene. This consideration is at the basis of the study presented here.  
Indeed, several snoRNA-containing host genes are acknowledged players in cancer 
development. For instance ribosomal proteins (RPs), like RPL5, which has been shown to be a tumor 
suppressor frequently deleted or altered in multiple cancer types, (reviewed in [33], or of other RPs, 
[34]. Likewise, translation initiation (EIF1A, EIF4A, EIF4G) and elongation (EEF1B2, EEF2) factors are 
well-known to play a role in cancer [35,36], as well as ribosome biogenesis related factors, like the 
pseudouridine synthase dyskerin [37] and the 2′-O-methyltransferase fibrillarin [38]. In addition, 
non-coding host genes have recently been found to be involved in cancer onset or progression, for 
example ZFAS1 [39], GAS5 [40], and MEG8 [41]. On top of these, multiple host genes are known 
regulators of cell metabolism, cell cycle, cell adhesion, and cell signaling, and their de-regulation 
therefore may be involved in cancer development.  
When considering CNA, amplification of snoRNA and host genes sequences were found to be 
most frequent event, with deep deletions occurring less frequently, suggesting that, in the majority 
of cases, in order to sustain their growth cancer cells, may take advantage of snoRNA/host genes 
overexpression. This finding is in contrast with a previous study, performed on TCGA datasets, 
which indicated that CNA deletions, and not amplifications, were the more frequent event, [42], but 
our observations fit well with the known functions of these genes in support of cell growth [3]. 
In our analysis, a relevant proportion (almost 40%) of snoRNA/host gene couples never turned 
out to be altered in any tumor type, suggesting that these genes are essential for basic cellular 
functions conserved within cancer cells, or, alternatively, that they do not play any significant role in 
neoplastic transformation. Conversely, 10% of snoRNA/host genes couples are found altered in all 
the tumor types considered (although with important frequency variability amongst different 
tumors), suggesting that their dysregulation might contribute to tumor development independently 
of the tissue of origin.  
Intriguingly, we found surprising the result that some CNA events do not co-occur in intronic 
snoRNA and matched host gene. This event was found more frequently in the sense of CNA of the 
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host gene as opposed to the snoRNA, but in some cases also in the converse direction. This 
unexpected finding could perhaps be explained by the postulation that snoRNAs are mobile genetic 
elements and therefore in tumors they may duplicate or insert in different positions of the genome 
[43]. 
Our analyses highlighted different CNA events, involving intronic snoRNAs and matched host 
genes, which are worth consideration. Among these, we found an overlap in the amplification 
frequencies of three different snoRNA/host gene couples, namely SNORA63/EIF4A2, 
SNORA63E/LINC00888, SNORD66/EIF4G1, in five different cancer types: HNSC, KIRC, SKCM, OV, 
and GBM. All these genes map to the same chromosomal location, 3q27, which also hosts different 
oncogenes (like TERT, PI3KCA, and BCL6) and has been shown to be frequently amplified in 
squamous cell carcinomas with different localizations (lung [44], esophagus [45], mouth [46]), in 
lymphomas [47], and in lung cancers different from LUSC (i.e., small cell lung carcinomas and 
adenocarcinomas [48]). Although it is difficult to speculate a possible mechanism for specific 
snoRNA/host gene CNA contribution to cancer onset, it is worthwhile to consider that the 
snoRNAs/host gene couples highlighted for being altered in multiple cancer types (Section 3.3) have 
already been recognized for having a specific biological relevance, which could be linked to clinical 
relevance in many cancer types (Table 2). 
Table 2. Relevance of snoRNA/host gene couples for which CNAs recur more frequently in multiple 
cancer types.  
snoRNA 
Host gene 
Known 
Target 
Biological Relevance 
Clinical  
Relevance 
 
References 
SNORA63 
 
 
 
 
EIF4A2 
28S rRNA  
U4390  
(Helix 89) 
 
 
-- 
Control of translation initiation, 
elongation and termination 
Translation initiation 
None reported 
 
 
 
 
Inversely correlates with 
prognosis in COAD, NSCLC, 
BRCA 
[49–51] 
SNORA63E 
LINC00888 
Unknown 
-- 
-- 
None reported 
Increased in SKCM 
 
[52] 
SNORD66 
 
 
EIF4G1 
18S rRNA C1272 
(Helix 32) 
-- 
Translation initiation 
 
Translation initiation 
Biomarker of NSCLC in 
sputum, plasma and tissue; 
correlates to overall survival in 
NSCLC 
Inversely correlates with 
prognosis in BRCA, OV, 
NSCLC, PDA 
[53–58] 
SNORA15 
 
 
CCT6A 
18S rRNA U1367 
(Helix 37) 
-- 
 
 
 
Activation of TGFbeta signaling 
None reported 
 
 
Correlates with negative 
prognosis in HCC 
[59,60] 
SNORA14B 
 
 
TOMM20 
18S rRNA U966 
(Helix 23) 
-- 
E site/translation elongation 
 
Increases mitochondrial ATP 
synthesis 
None reported 
 
 
Overexpressed in various 
cancer types; potential 
therapeutic target in COAD 
[61,62] 
SNORD72 
 
 
RPL37 
5.8S rRNA U55 
(Helix 6) 
-- 
Formation of the ribosome small 
subunit 
Activator of ribosomal stress pathway 
None reported 
 
 
Overexpressed in PC 
[33,63,64] 
 
SNORA56 
 
 
DKC1 
28S rRNA U1664 
(Helix 37) 
-- 
Putative mRNA/tRNA binding 
rRNA pseudouridylation; regulates 
translational fidelity and Cap-
independent translation; Telomere 
binding 
None reported 
 
 
Negatively correlates with 
survival in BRCA, and NSCLC 
[37,65–68] 
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SNORA36A 
 
 
 
 
DKC1 
18S rRNA U105 
(Helix 7) and 
U1244 (Helix 31) 
-- 
Binding of factors to form the 90S 
preribosome (H7); 
Translation elongation (H31) 
See above 
None reported 
 
 
 
 
See above 
[69,70] 
 
SNORA70G 
 
 
 
 
RAP1B 
18S rRNA U1692 
(Helix 28) 
 
 
-- 
Small ribosomal subunit maturation; 
translation initiation 
GTPase regulating cell adhesion, 
migration, polarity, differentiation, 
growth and angiogenesis 
None reported 
 
 
 
 
Negatively correlates with 
prognosis in GC; up-regulated 
in ESCC 
[71–73] 
 
 
COAD: colon adenocarcinoma; NSCLC: non-small cell lung carcinoma; BRCA: breast cancer; SKCM: 
skin cutaneous melanoma; OV: ovarian cancer; PDA: pancreatic ductal adenocarcinoma; HCC: 
hepatocellular carcinoma; PC: prostate cancer; GC: gastric cancer; ESCC: esophageal squamous cell 
carcinoma. 
When considering expression data for the three overlapping snoRNA/host gene couples 
mentioned above, only the SNORA63/EIF4A2 turned out to be over-expressed in squamous cell 
carcinomas of head and neck and of the lung, suggesting either that in most cancer types 
snoRNA/host gene CNA is an early event in tumor development, and expression of the two is first 
boosted, and later on is shut down, or alternatively that amplification of SNORA63/EIF4A2 is a 
passenger event, consequent to the proximity to other cancer driver genes in the chromosome. Even 
though further studies are necessary to shed light on this matter, a role for EIF4A2 in lung cancer and 
in other cancer types has been previously proposed [50,74,75], indicating that these mutations might 
have a driver, rather than passenger, role in tumorigenesis. In addition, in the datasets we analyzed, 
the overexpression of snoRNA63 is detectable in half of the EIF4A2 overexpressing LUSC patients 
and in about one fourth of the HNSC patients, suggesting that co-expression of the host gene and the 
intronic snoRNA is not co-regulated, and implying a possible, still unexplored, role for SNORA63 
overexpression in cancer. Similar considerations can of course be extended to other snoRNA/host 
gene couples, for which a correspondence in CNA and expression is not apparent. Among these, 
SNORA15/CCT6A, which we found genetically altered in a high percentage of HNSC, KIRC, SKCM 
and UCEC patients, but overexpressed in around 5% of SKCM, BRCA, and LUSC patients (with an 
amplification/overexpression correspondence only for melanomas, where CCT6A overexpression 
has previously been linked to drug resistance [76], but the contribution of SNORA15 remains 
unexplored). 
In addition, our expression analysis identified two snoRNA/host gene couples 
(SNORA71E/SNHG11 and SNORA5C/TBRG4) which are transversally up-regulated in different 
cancer series, indicating that they may have a role in cellular mechanisms of tumorigenesis. Even 
though the relevance of these two snoRNAs has not yet been reported, different groups have reported 
alterations in SNHG11 and TBRG4 in different cancer types [77–81]. 
One unexpected result that we observed in tumors is that downregulation has never been 
observed for any snoRNA within the queried datasets. This is particularly surprising when taking 
into account that, in a limited number of cases, snoRNA sequences were found to be subject to deep 
deletions. Importantly, the majority of TCGA-based studies analyzed snoRNA expression from 
library preparation methodologies that enrich for small RNAs (less than 200 nucleotides in length), 
implying the loss of a large fraction of snoRNAs of middle-to-large size [19]. The frequency of these 
alterations could therefore be largely underestimated and perhaps some of the surprising results 
observed in snoRNA expression datasets (including those of over-expression) ought to be 
reconsidered in light of these methodological limitations.  
A previous large study interrogated the TCGA database for snoRNA CNA, expression alteration 
and gene methylation on more than 10,000 samples across 31 cancer types [19]. This study identified 
46 snoRNAs relevant for human cancer. Importantly, 9 of these snoRNAs were also identified by our 
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analysis with a different methodological approach, namely SNORA21, SNORA56, SNORD12B, 
SNORD12C, SNORD41, SNORD15A, SNORD15B, SNORD72, SNORD102, confirming the 
observation that these snoRNAs play an important role in cancer development. However, with the 
exception of the few selected cases discussed above, for most of the observed alterations precise 
mechanistic insights regarding their role in tumorigenesis are currently lacking. In principle, changes 
in the expression of guide snoRNAs should impact upon the modification of their specific target site. 
The majority of cases involve rRNA, consequently ribosomal activity may be affected, potentially 
impacting on the translatome. However snoRNAs are known to have different activities such as 
regulation of splicing and mRNA abundance tRNA methylation, etc. (see [15] for review), therefore 
changes in their expression may modify gene expression at multiple levels.  
To understand how alterations of snoRNA genes can contribute to cancer, new studies 
implementing adequate technical approaches on tumor material of human origin are required to 
allow for the characterization of the biological significance of mutation and/or alteration of the 
expression of snoRNAs and their host genes. 
5. Conclusions 
Altogether, our findings suggest that studies analyzing CNA and/or expression deregulation of 
snoRNA genes and/or of host genes, should take into account the differential contribution to cancer 
development of both snoRNAs and host genes. Indeed, snoRNAs and their host genes may contribute 
to cancer onset, progression, and response to therapies in conjunction or independently.  
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